EPS for JMP Group (JMP) Expected At $0.02; SILENCE THERAPEUTICS PLC ORDINARY SHARES (SLNCF) Sellers Decreased By 12.5% Their Shorts

April 16, 2018 - By Marguerite Chambers

Silence Therapeutics plc (OTCMKTS:SLNCF) Logo

SILENCE THERAPEUTICS PLC ORDINARY SHARES (OTCMKTS:SLNCF) had a decrease of 12.5% in short interest. SLNCF’s SI was 700 shares in April as released by FINRA. Its down 12.5% from 800 shares previously. With 300 avg volume, 2 days are for SILENCE THERAPEUTICS PLC ORDINARY SHARES (OTCMKTS:SLNCF)’s short sellers to cover SLNCF’s short positions. It closed at $2.13 lastly. It is down 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect JMP Group LLC (NYSE:JMP) to report $0.02 EPS on April, 25.They anticipate $0.11 EPS change or 122.22% from last quarter’s $-0.09 EPS. JMP’s profit would be $431,035 giving it 63.75 P/E if the $0.02 EPS is correct. After having $0.16 EPS previously, JMP Group LLC’s analysts see -87.50% EPS growth. The stock increased 0.59% or $0.03 during the last trading session, reaching $5.1. About 22,973 shares traded. JMP Group LLC (NYSE:JMP) has declined 15.70% since April 16, 2017 and is downtrending. It has underperformed by 27.25% the S&P500.

Silence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company has market cap of $170.59 million. The firm creates short interfering RNA molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It currently has negative earnings. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Investors sentiment decreased to 0.86 in 2017 Q4. Its down 0.43, from 1.29 in 2017Q3. It fall, as 4 investors sold JMP Group LLC shares while 3 reduced holdings. 2 funds opened positions while 4 raised stakes. 2.90 million shares or 4.88% more from 2.77 million shares in 2017Q3 were reported. California Pub Employees Retirement Systems, California-based fund reported 57,700 shares. Fmr Limited has invested 0% in JMP Group LLC (NYSE:JMP). Essex Investment Mgmt Llc stated it has 0.04% of its portfolio in JMP Group LLC (NYSE:JMP). Bridgeway Cap Incorporated holds 0.01% or 116,451 shares. Renaissance Technologies Limited Liability Co invested in 0% or 84,833 shares. Continental Ltd Llc, Illinois-based fund reported 295,326 shares. Us Bancshares De owns 10,000 shares or 0% of their US portfolio. Arbiter Capital Management Ltd Liability holds 0.01% of its portfolio in JMP Group LLC (NYSE:JMP) for 23,589 shares. Deutsche Fincl Bank Ag, a Germany-based fund reported 122,216 shares. Price T Rowe Associate Md reported 1.01 million shares or 0% of all its holdings. Royal National Bank Of Canada has 0% invested in JMP Group LLC (NYSE:JMP) for 41,762 shares. 77,868 were reported by Morgan Stanley. Putnam Invs Ltd Company holds 137,700 shares or 0% of its portfolio. Manufacturers Life Ins The reported 189 shares stake. Gsa Capital Prtn Llp has 0% invested in JMP Group LLC (NYSE:JMP) for 11,483 shares.

JMP Group LLC (NYSE:JMP) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>